The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS

,

[1]  P. Campbell,et al.  SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS , 2020, Blood.

[2]  M. Cazzola,et al.  Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. , 2020, The New England journal of medicine.

[3]  P. Greenberg,et al.  Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review , 2018, British journal of haematology.

[4]  A. Savic,et al.  Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study , 2018, Leukemia.

[5]  B. Leber,et al.  A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry , 2017, Annals of Hematology.

[6]  B. Leber,et al.  ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems , 2017, American journal of hematology.

[7]  M. Moarii,et al.  SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells. , 2017, Blood.

[8]  S. Linnarsson,et al.  Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. , 2014, Cancer cell.

[9]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[10]  M. Cazzola,et al.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.

[11]  Peter J Campbell,et al.  Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.

[12]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[13]  C. Lacombe,et al.  Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction , 1999, British journal of haematology.

[14]  L. Kanter‐Lewensohn,et al.  Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. , 1997, Leukemia research.

[15]  M. Koury,et al.  Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. , 1990, Science.